A phase 2 clinical trial (NCT02734004) of olaparib and programmed cell death ligand 1 (PDL-1) inhibitor durvalumab (Imfinzi) in platinum-sensitive relapsed germline BRCA1/2-mutated ovarian cancer is an example [66]. Here, BRCA1 is linked to ovarian cancer.